The FDA and Biogen Taking Heat for Aduhelm’s Approval Process
Over a year after the FDA approved Biogen’s Alzheimer’s drug, Aduhelm, on the accelerated approval pathway, the U.S. House of Representatives published a report outlining the atypical processes leading to the drug’s approval. The report faults the FDA for abnormalities in documentation protocol, not adequately representing differing views within the regulatory agency, shifting to accelerated approval in a substantially short timeframe, and approving the drug for a broad label despite a lack of clinical evidence in a wider population. Biogen is under fire for accepting the broad label, knowing it did not test the drug in a broad population and setting a high price, and planning for substantial marketing costs, despite knowing the potential impact on patients and the Medicare system.
GO Prime with only $1.49 now
LATEST
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02